Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.41 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568571 | 0.91 | DGAT1 (0.42) | MRGPRX4KIF11MAPK1MAP2K4MAPK6 | |
| SCHEMBL4568570 | 0.89 | MRGPRX4 (0.42) | MRGPRX4CNR1MAPK1MAP2K4MAPK6 | |
| SCHEMBL4568196 | 0.88 | MAPT (0.42) | CYP1A2MCL1 | |
| SCHEMBL4568206 | 0.86 | TUBB4A (0.43) | CNR1MAP2K4 | |
| SCHEMBL15975189 | 0.86 | MCL1 (0.52) | CNR1MCL1 | |
| SCHEMBL11979687 | 0.86 | MCL1 (0.44) | CNR1MCL1 | |
| SCHEMBL4568212 | 0.85 | KIF11 (0.45) | KIF11 | |
| SCHEMBL15998649 | 0.85 | KDM4E (0.40) | PTGER1 | |
| SCHEMBL4568232 | 0.85 | MRGPRX4 (0.41) | MRGPRX4CYP1A2CYP2C9CYP2C19MCL1 | |
| SCHEMBL3701174 | 0.84 | MDM4 (0.51) | CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104151292-A | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL | 2014-11-19 | — | — | CN | claimed |
| CN-104151292-A | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL | 2014-11-19 | — | — | CN | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MRGPRX4 273/4885CNR1 4/4885KIF11 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.